In prostate cancer, RNF43 genetic mutations are present in primary and metastatic disease (≤1% and 1.8–2.5%, respectively, Tables S1–S4) [64,65,66], with around half of the variants occurring in the C-terminus. This evidence concerns the gene RNF43 and prostate carcinoma.